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Abstract 20 
PRKAG2 encodes the γ2-subunit isoform of the 5’ AMP-activated protein kinase (AMPK), a 21 
heterotrimeric enzyme with major roles in regulation of energy metabolism in response to cellular 22 
stress. Mutations in PRKAG2 have been implicated in a unique hypertrophic cardiomyopathy 23 
(HCM) characterized by cardiac glycogen overload, ventricular preexcitation and hypertrophy. We 24 
identified a novel, de novo PRKAG2 mutation (K475E) in a neonate with prenatal onset of HCM. 25 
We aimed to investigate the cellular impact, signaling pathways involved and therapeutic options 26 
for K475E mutation using cells stably expressing human wild type (WT) or the K475E mutant. In 27 
HEK293 cells, the K475E mutation induced a marked increase in the basal phosphorylation of T172 28 
and AMPK activity, reduced sensitivity to AMP in allosteric activation and a loss of response to 29 
phenformin. In H9c2 cardiomyocytes, the K475E mutation induced inhibition of AMPK and 30 
reduced response to phenformin and increases in phosphorylation of P70S6K and 4E-BP1. Primary 31 
fibroblasts from the patient with the K475E mutation also showed marked increases in 32 
phosphorylation of P70S6K and 4E-BP1, compared to those from age-matched, non-diseased 33 
controls. Moreover, overexpression of K475E induced hypertrophy in H9c2 cells which was 34 
effectively reversed by treatment with rapamycin. Taken together, we have identified a novel, de 35 
novo infantile-onset PRKAG2 mutation causing HCM. Our study suggests the K475E mutation 36 
induces alteration in basal AMPK activity and results in a hypertrophy phenotype involving the 37 
mechanistic target of rapamycin (mTOR) signaling pathway, which can be reversed with 38 
rapamycin. 39 
 40 
 41 
New & Noteworthy: We identified a novel, de novo PRKAG2 mutation (K475E) in the CBS3 42 
repeat, a region critical for AMP binding but with no previous reported mutation. Our data suggest 43 
the mutation affects AMPK activity, activates cell growth pathways and results in cardiac 44 
hypertrophy which can be reversed with rapamycin. 45 
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Introduction: 51 
 52 
Mutations in PRKAG2 gene, encoding the γ2 regulatory subunit isoform of AMP-activated 53 
protein kinase (AMPK), cause a wide spectrum of cardiac phenotypes, including Wolff-Parkinson-54 
White (WPW) syndrome (ventricular preexcitation), hypertrophic cardiomyopathy (HCM), 55 
conduction system disease, significant glycogen accumulation in myocytes and sudden death 56 
(2,6,10,18,21). AMPK is known as a cellular energy sensor and a major regulator of whole-body 57 
energy homeostasis (15). The γ subunit of AMPK is the regulatory subunit and contains four 58 
tandem repeats of a sequence called cystathionine β-synthase (CBS) motif. These motifs act in pairs 59 
to form two “Bateman domains” - binding sites for AMP and ATP (4,29). During cellular energy 60 
deficiency (increased ratio of AMP/ATP), binding of AMP to the Bateman domains activates 61 
AMPK by inducing phosphorylation of T172 in the α subunit (kinase domain) (12,13). Activation 62 
of AMPK in many tissues, including the heart, results in inhibition of ATP-consuming processes 63 
and activation of catabolic processes that favor ATP generation. 64 
To date, many PRKAG2 mutations have been reported. The majority of these mutations are 65 
heterozygous missense mutations within one of the four CBS domains but mutations can happen 66 
near the N-terminal, C-terminal or in a linker region between two CBS domains (Table 1).  67 
Case presentation: We encountered a child who presented with an abnormal 27-week prenatal 68 
ultrasound, consistent with HCM. At birth, the child was noted to have significant murmur. 69 
Echocardiograms confirmed the diagnosis. Electrocardiograms revealed extremely short PR interval 70 
and combined ventricular hypertrophy (Figure 1C). Molecular testing for a hypertrophic 71 
cardiomyopathy panel revealed a novel, de novo likely pathogenic variant in the PRKAG2 gene 72 
[AAA (lysine 475) to GAA (glutamic acid) or K475E]. This variant is located in the CBS3 repeat, 73 
an area that has no previous report of mutation and is conserved in all species (Table 1, Figure 1B). 74 
At three years of age, the child has modest HCM and is on supportive medication. She is otherwise 75 
developing normally. Family investigation: No family history of sudden cardiac death. Neither 76 
parent had abnormal cardiac echocardiograms or electrocardiograms. Molecular testing for 77 
PRKAG2 in both parents was normal (Figure 1A). 78 
To investigate the significance of the de novo K475E mutation on the AMPK complex, we 79 
stably expressed human PRKAG2 wild type (WT) and K475E in HEK293 cells and H9c2 80 
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cardiomyocytes to examine AMPK activity, biochemical function and signaling pathways involved 81 
resulted from the K475E mutation. Primary fibroblasts from the patient with the K475E mutation 82 
were obtained for clinical purposes and institutional review board approval was obtained for further 83 
research study. Primary fibroblasts obtained from commercial sources and age- and sex-matched 84 
individuals were obtained and used as controls. The potential of mechanistic target of rapamycin 85 
(mTOR) inhibition as a targeted therapeutic approach for mutation-induced HCM was also 86 
investigated using the rat H9c2 embryonic cardiomyocytes. We demonstrated that the K475E 87 
mutation induced changes in the AMPK complex in a way very different from other PRKAG2 88 
mutations. The K475E mutation in H9c2 cells results in activation of cell growth pathways and 89 
hypertrophy, which can be attenuated by inhibition of mTOR. 90 
91 
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Methods: 92 
Genetic testing 93 
Hypertrophic cardiomyopathy next generation sequencing panel testing was sent to a CLIA 94 
(Clinical Laboratory Improvement Amendments) certified laboratory (GeneDx, Gaithersburg, MD) 95 
December 2010. Genomic DNA was extracted, amplified and sequenced by solid-state sequencing -96 
by-synthesis process. The DNA sequence was assembled and analyzed in comparison with the 97 
published genomic reference sequences. This panel included the complete coding and splice region 98 
of the following eighteen genes known to be associated with HCM: MYH7, MYBPC3, TNNT2, 99 
TNNI3, TPM1, ACTC, MYL3, MYL2, LAMP2, PRKAG2, GLA, CAV3, MTTG, MTTI, MTTK, 100 
MTTQ, TTR, TNNC1. The presence of potentially disease-associated sequence variant was 101 
confirmed by conventional dideoxy DNA sequence analysis.  102 
 103 
Cell Culture 104 
HEK293 and H9c2 rat fetal cardiomyocytes were grown in Dulbecco’s Modified Eagle medium 105 
(Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum (Atlanta Biologicals, 106 
Flowery Branch, GA) and 1% (V/V) penicillin-streptomycin (Sigma) in a humidified atmosphere 107 
containing 5% CO2 at 37 °C. Cells were grown to 70% confluence and synchronized overnight in 108 
serum-free medium prior to experiments (33).  109 
Institutional Research Board approval was obtained to use patients’ dermal fibroblasts. Multiple 110 
age-matched control neonatal fibroblasts were obtained from commercial sources and an age- and 111 
sex-match control was obtained from the Cytogenetics Laboratory, Women & Infant’s Hospital of 112 
Rhode Island. Fibroblasts were cultured in Medium 106 (Gibco) supplemented with 2% (v/v) fetal 113 
bovine serum, 2% (v/v) Low Serum Growth Supplement (LSGS) and 1% (v/v) Penicillin-114 
streptomycin (Sigma). The final concentrations of the components in the LSGS were: 115 
hydrocortisone (1 µg/ml), human epidermal growth factor (10 ng/ml), basic fibroblast growth factor 116 
(3 ng/ml), and heparin (10 µg/ml). The cells were used between passages 2 and 6. 80-100% 117 
confluent cells were used for western blot experiment. Media was changed once daily starting at 118 
day 2 and until the termination of the experiment. 119 
 120 
Plasmids 121 
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Full-length human WT and K475E mutant PRKAG2 (FLAG-tagged from a tetracycline-122 
inducible promoter) were generated as described (14) and transfected into HEK293 or H9c2 cells 123 
using Lipofectamine 2000 according to the manufacturer’s instructions (Invitrogen). To establish 124 
multiple clones, individual single cells were isolated and screened for neomycin resistance. 125 
 126 
Immunoprecipitation kinase assays of AMPK 127 
AMPK activity was assayed using AMARA peptide on immunoprecipitated HEK293 cell 128 
lysates as described (14).  129 
 130 
Western Blotting  131 
Protein levels were evaluated by Western blotting as previously described (33) using phospho-132 
specific antibodies against p70S6K1 (T-389, catalog  #9234 and T-421/S-424, catalog #9204), Akt 133 
(S-473, catalog #9271 and T-308, catalog #9275), AMPKα (T172, catalog #5832) and eukaryotic 134 
translation initiation factor 4E (eIF4E)-binding protein1 (4E-BP1, T-37/46, catalog #2855;  S-65, 135 
catalog #9451 and T-70, catalog #9455); and antibodies against total p70S6K1 (catalog #2708), Akt 136 
(catalog #9272),  AMPKα (catalog #2531) and 4E-BP1 (catalog #9452) (Cell Signaling 137 
Technology, Danvers, MA). The intensity of bands from Western blots was scanned with 138 
densitometry and analyzed digitally with Image J software (NIH). 139 
 140 
H9c2 cell hypertrophy and cell size measurement 141 
H9c2 embryonic cardiomyocytes (1000 cells per 60x15 mm plate) were treated with vehicle, 142 
200 nM Angiotensin II (AT2, Tocris, Bristol, UK), 50 nM rapamycin (Selleckchem, Houston, TX) 143 
or AT2 in combination with rapamycin for 24 hours. Cells were washed 3 times with Dulbecco's 144 
Phosphate-Buffered Saline (DPBS) then incubated with green-fluorescent Calcein AM (1µg/mL, 145 
Life Technologies) for 20 minutes at 37 °C. Cells were washed 5 times with DPBS. Cell size was 146 
assessed by fluorescence microscopy using an inverted microscope at 20x objective (Nikon Eclipse 147 
TE2000-E, CCD camera). Sixty to eighty random cell images were taken per plate and the cell 148 
areas were determined by Image J software. In another series of related experiments, H9c2 cells 149 
were treated with or without rapamycin for 3.5, 4, or 5 days. At each time point cells were stripped 150 
and re-plated exactly 24 hours before being harvested and stained for fluorescence microscopy. Cell 151 
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hypertrophy was also confirmed using flow cytometry. Cells were trypsinized and analyzed by flow 152 
cytometry using a FACSCanto™ system (BD Biosciences, Franklin Lakes, NJ). Forward scatter 153 
(FSC) was used to measure cell volume. For each condition 10,000 cells were counted. FSC 154 
detector gain was kept constant between samples to allow direct comparison of samples. 155 
 156 
Statistics 157 
Statistical significance of the differences between groups was analyzed using paired Student’s t 158 
test or ANOVA followed by Newman-Keuls test. All data were expressed as mean ± S.E. based on 159 
results derived from three to four independent experiments. A probability of P < 0.05 was 160 
considered to represent a significant difference. 161 
  162 
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Results: 163 
Genetic testing result 164 
The proband was found to carry a heterozygous novel missense likely pathogenic variant in 165 
PRKAG2 gene. The nucleic acid substitution at cDNA level was c.1423 A>G resulting in amino 166 
acids alteration from lysine to glutamic acid (K475E).  This change in PRKAG2 has not been 167 
published and is not a known benign polymorphism. K475E represents a nonsynonymous 168 
substitution of negatively charged glutamic acid for positively charged lysine residue in a highly 169 
conserved across species throughout evolution and gene isoforms. In addition, in silico analysis 170 
(PolyPhen2) predicts this change to be damaging to the structure/function of the protein. Mutation 171 
affecting nearby codons (485, 487 and 488) have been published in association with cardiac 172 
hypertrophy further supporting the functional importance of this region of the protein (2,3,21). 173 
Furthermore, K475E was not observed in 704 control chromosomes of varying ethnic backgrounds 174 
tested at the laboratory, indicating it is not a common benign variant. In addition, the parents who 175 
are both clinically asymptomatic, had normal ECG and cardiac echo were not found to carry this 176 
variant. Base on this information, we concluded that the K475E in PRKAG2 is most consistent with 177 
a de novo pathogenic variant.  178 
 179 
The K475E mutation markedly increases basal AMPK activity and reduces response to phenformin 180 
in HEK293 cells 181 
To investigate the molecular effects of the K475E mutation on the function of the AMPK 182 
complex, we generated HEK-293 cells stably expressing either the human WT or K475E mutant 183 
FLAG-tagged γ2 from a tetracycline-inducible promoter. We have shown previously using this 184 
system that the expressed γ2 subunit binds to the endogenous α and β subunits (primarily α1 and β1 185 
in HEK-293 cells), partially replacing the endogenous γ1 subunit (14). Following induction with 186 
tetracycline, AMPK complexes containing the WT or K475E γ2 subunits were immunoprecipitated 187 
from unstressed cells using anti-FLAG antibodies and their activities determined at varying AMP 188 
concentrations. When assayed in the absence of AMP, the activity of the K475E complex was 8-189 
fold higher than that of the WT complex (Figure 2A). However, while the WT complex was 190 
allosterically activated almost 4-fold by low concentrations of AMP (half-maximal effect, 6 µM), 191 
the K475E mutant was only modestly activated (about 50%) and then only at much higher 192 
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concentrations (EC50 ≈ 90 µM). The different degrees of allosteric activation of the WT and K475E 193 
mutant by AMP were particularly evident when the activities were expressed relative to the 194 
activities measured in the absence of AMP (Figure 2B). 195 
 We next compared the effects of metabolic stress induced by the drug phenformin on AMPK in 196 
HEK-293 cells stably expressing WT γ2, the K475E mutation, or another γ2 mutation (R531G), 197 
which is associated with an inherited form of hypertrophic cardiomyopathy with childhood onset 198 
(11). The WT, K475E or R531G complexes were immunoprecipitated using anti-FLAG antibodies 199 
and their activities measured at optimal AMP concentration (200 µM). As expected, phenformin 200 
caused a 4-fold increase in WT AMPK activity that was associated with a similar increase in T172 201 
phosphorylation (Figure 3). As reported previously (14), complexes containing the R531G mutation 202 
exhibited modest (1.5-2-fold) increases in basal activity and T172 phosphorylation compared with 203 
the WT (although these differences were not statistically significant in this dataset), but there were 204 
no further increases in these parameters in response to phenformin. By contrast, complexes 205 
containing the K475E mutation exhibited large increases in basal activity and T172 phosphorylation 206 
(5- and 7-fold, respectively) compared to the WT, although once again there were no further 207 
increases in these parameters in response to phenformin (Figure 3). Thus, the K475E mutation 208 
yields a much larger increase in basal and kinase activity and T172 phosphorylation than the R531G 209 
mutation, but like the latter has a greatly reduced sensitivity to AMP and/or ADP, both for allosteric 210 
activation and for enhanced T172 phosphorylation. 211 
 We also used atomic co-ordinates from crystal structures of partial AMPK complexes with 212 
bound AMP, ADP or ATP (9,31), to examine the location of K475 with respect to these regulatory 213 
nucleotides. The available structures are of complexes containing γ1 rather than γ2, but K475 is 214 
conserved in rat γ1 as K242. Interestingly, the nitrogen atom on the K242 side chain is within 4-5 Å 215 
of free oxygen atoms of the α-, β- or γ-phosphate groups of AMP, ADP or ATP bound in site 1 216 
(Figures 4A-C), suggesting that K242 forms electrostatic interaction with phosphate groups of all 217 
three nucleotides. We also noted that K242 was located close to R223, a residue within the CBS3 218 
repeat that is conserved in all vertebrate γ subunit sequences. Although the side chain of R223 219 
points away from K242 (and the nucleotide phosphate groups) in the structures determined, if K475 220 
was replaced with glutamate it seems feasible that the side chain of R223 could rotate to form a salt 221 
bridge with it. 222 
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 Database searches showed that a lysine equivalent to K242 or K475 is conserved in all vertebrate 223 
γ1 and γ2 isoforms (illustrated by the human and chicken sequences), and in Drosophila 224 
melanogaster, Caenorhabditis elegans (γ1 isoform) and Giardia lamblia (Figures 4D, Figure 1B). 225 
In vertebrate γ3 isoforms and in some other invertebrate orthologues there is another basic residue 226 
(arginine) at this position. Figure 4D also shows that a basic residue is not conserved at this position 227 
in fungi (Schizosaccharomyces pombe and Saccharomyces cerevisiae) or higher plants (Arabidopsis 228 
thaliana); interestingly, the orthologues in these species are not allosterically activated by AMP. 229 
 230 
The K475E mutation decreases AMPK activity, reduces response to phenformin and induces 231 
hypertrophy in H9c2 cells 232 
Since we are studying a human gene mutation causing HCM, it would be informative to 233 
examine changes in AMPK induced by the K475E mutation in a cardiac context. Multiple 234 
individual clones of H9c2 cells stably expressing either the WT or K475E mutant were established 235 
and Western blots were performed on cell lysates. The WT and K475E expressing H9c2 236 
cardiomyocytes were treated with or without phenformin for 1, 4, or 24 hours. In vehicle controls, 237 
the K475E- expressing cells had significantly reduced phosphorylation of AMPKα (T172), 238 
compared to WT- expressing cells (Figure 5A & B). Phenformin induced significantly increases in 239 
AMPKα phosphorylation in all the time points tested in both the WT- and K475E- expressing cells. 240 
The effect of phenformin, however, was significantly reduced in the K475E- expressing cells, 241 
compared to the WT- expressing cells (Figure 5A & B). The cell size difference between the WT- 242 
and K475E-expressing H9c2 cells was analyzed using flow cytometry. We found a small but 243 
noticeable increase in cell size of the K475E mutant-expressing cells as compared to WT-244 
expressing cells (Figure 5C). 245 
 246 
Effects of K475E mutation on p70S6K, Akt and 4E-BP1 in H9c2 cardiomyocytes and primary 247 
fibroblasts 248 
Western blots were performed on cell lysates from H9c2 cell expressing the WT or K475E. As 249 
shown in Figure 6, K475E-expressing cells had significantly increased phosphorylation of p70S6K 250 
and 4EBP1, compared to the WT-expressing cells. Phosphorylation at T-389 is critical for p70S6K 251 
activation and is considered rapamycin-sensitive (7). 4E-BP1, a translation repressor protein, 252 
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inhibits cap-dependent translation by binding to eIF4E. Phosphorylation of 4E-BP1 at multiple 253 
residues leads to its dissociation from eIF4E thus results in activation of cap-dependent mRNA 254 
translation (25). Therefore, phosphorylation of p70S6K and 4E-BP1 was used as readout for 255 
cellular growth. Phosphorylation of 4E-BP1 at T37/T46, S65 and T70 were all significantly 256 
increased in K475E-expressing cells, compared to WT-expressing cells (Figure 6). In contrast, Akt 257 
phosphorylation (S473, T308) was not changed. 258 
Western blot experiments described above were repeated using primary fibroblast from the 259 
patient with the K475E mutation and multiple age- and sex-matched controls. Similarly, fibroblasts 260 
carrying the K475E mutation had significant increases in phosphorylation of p70S6K and 4E-BP1, 261 
compared to the controls (Figure 7). Again, phosphorylation of Akt was not changed.  262 
Taken together, these results suggest the K475E mutation results in an Akt-independent 263 
activation of cell growth pathway. 264 
 265 
Inhibition of mTOR by rapamycin reversed angiotensin II-induced H9c2 cell hypertrophy and the 266 
K475E cardiac phenotype in vitro 267 
Induction of H9c2 cell hypertrophic responses by angiotensin II (Ang II) has been demonstrated 268 
to be similar to those in primary neonatal cardiomyocytes (30). To examine if inhibition of mTOR 269 
can reverse Ang II-induced hypertrophy, WT- and K475E-expressing cells were treated with 270 
vehicle, Ang II alone, rapamycin alone or Ang II + rapamycin for 24 hours. Cells were 271 
immunofluorescence-stained and cell areas were assessed by microscopy. In all treatment groups 272 
including the vehicle control group, the K475E-expressing H9c2 cells had a significant increase in 273 
cell size, compared to the WT-expressing cells (Figure 8). Ang II treatment induced hypertrophy in 274 
both WT- and K475E-expressing cells. Rapamycin treatment alone did not change cell size but 275 
effectively abrogated cell hypertrophy induced by Ang II. These results demonstrate mTOR 276 
inhibition by rapamycin can reverse Ang II-induced cell hypertrophy in both WT- and K475E-277 
expressing H9c2 cells, but fails to ‘rescue’ the K475E phenotype as the K475E-expressing cell size 278 
remained significantly increased, compared to the WT-expressing cells, in all treatment groups.  279 
One possibility for the lack of phenotype ‘rescue’ following rapamycin treatment is that a 24-280 
hour treatment regimen may not be sufficient. We therefore examined the time-course effect of 281 
rapamycin on H9c2 cell hypertrophy. The WT- and K475E-expressing cells were treated with or 282 
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without rapamycin for 1, 3.5, 4, or 5 days. In both cell groups, cell size increased significantly after 283 
longer incubation time (over 3.5 Days, Figure 9A). While the cell size of WT-expressing cells 284 
reached a plateau at day 3.5, those of K475E-expressing continued to increase. In WT-expressing 285 
cells, treatment of rapamycin effectively reduced the increases in cell size on days 3.5 and 4 but the 286 
effect seemed to taper off on day 5. In contrast, the effect of rapamycin remained effective in 287 
reducing the size of K475E-expressing cells with the effect becoming even more obvious at day 5 288 
when the cell sizes of rapamycin-treated K475E-expressing cell were comparable to that of WT-289 
expressing cells at day 5 (Figure 9B). Taken together, these data demonstrated mTOR inhibition by 290 
rapamycin can be an effective therapeutic approach for K475E mutation induced hypertrophy. 291 
 292 
  293 
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Discussion: 294 
Mutations in PRKAG2 induce a wide range of cardiac phenotypes, including glycogen overload, 295 
ventricular preexcitation, conduction diseases and hypertrophy. Many mutations have an early-296 
onset cardiac phenotype, as the case for K475E. Given that identification of this disease can be 297 
challenging (patient with an infantile-onset mutations may die in utero or during early postnatal 298 
life) and misdiagnosis frequently happens (for example confusion with Pompe disease, a glycogen 299 
storage disease), it is likely the incidence of PRKAG2-induced HCM is underreported. Our study 300 
revealed a mutation located in the CBS3 repeat, which has no previous reported mutation, and 301 
behaved quite differently in terms of changes in AMPK activity and allosteric activation from other 302 
PRKAG2 mutations. Moreover, our data suggest that targeted therapy of PRKAG2-induced HCM 303 
using mTOR inhibition should be considered.  304 
Our molecular studies in HEK293 cells show that the K475E mutation has three effects on the 305 
regulation of the AMPK complex: (i) markedly increasing the basal phosphorylation of T172 and 306 
hence basal kinase activity; (ii) reducing the sensitivity to AMP in allosteric activation; (iii) 307 
preventing the increase in T172 phosphorylation observed in response to phenformin, which 308 
increases cellular ADP:ATP and AMP:ATP ratios. The three nucleotide-binding sites (1, 3 and 4) in 309 
the AMPK-γ subunit are numbered by convention according to the number of the CBS repeat that 310 
carries an aspartate side chain interacting with the 2'- and 3'-hydroxyls of the nucleotide ribose ring 311 
(17). The structural analysis illustrated in Figure 4 suggests that K242 in γ1 (equivalent to K475 in 312 
γ2) is involved in forming electrostatic interactions with phosphate groups of all three adenine 313 
nucleotides, AMP, ADP and ATP, in site 1. Interestingly, a lysine at this position is conserved in all 314 
vertebrate γ1 and γ2 isoforms, and also in some invertebrate orthologues such as that from 315 
Drosophila melanogaster; in vertebrate γ3 isoforms and many other invertebrate orthologues it is 316 
replaced by another basic residue, arginine. A basic residue at this position is not, however, 317 
conserved in the fungal and plant Arabidopsis thaliana, where allosteric activation by AMP is not 318 
observed (Figure 4D). The K475E mutation replaces the positively charged amine of lysine with the 319 
negatively charged carboxyl group of glutamate, potentially disrupting electrostatic interactions 320 
with all three nucleotides. Although it is difficult to predict the relative effects this might have on 321 
binding of the three nucleotides, if it had a larger effect on the binding of AMP than ATP it would 322 
be expected that higher concentrations of AMP would be required to displace ATP from site 1. 323 
15 
 
Consistent with this, the EC50 for allosteric activation of the K475E mutant by AMP was around 15-324 
fold higher than that of the wild type (Figure 2). The maximal degree of activation by AMP also 325 
appeared to be reduced, although analysis of this was hindered by the fact AMP starts to inhibit 326 
AMPK at concentrations above 200 µM, due to competition with ATP at the catalytic site. 327 
Xiao et al (32) originally proposed that the effects of AMP on allosteric activation were entirely 328 
due to binding at site 1, whereas the effects of AMP and/or ADP on T172 dephosphorylation were 329 
due to binding at site 3. Since K242 in γ1 only seems to interact with nucleotides in site 1, the 330 
model of Xiao et al (32) is consistent with our data showing that the K475E mutation markedly 331 
affects allosteric activation by AMP (Figure 2B). However, there were also major effects of the 332 
K475E mutation to increase the basal T172 phosphorylation and hence basal activity, while 333 
preventing further phosphorylation induced by phenformin-triggered metabolic stress in intact cells. 334 
These effects observed in HEK293 cells are less easy to explain using the simple model of Xiao et 335 
al (32). The three nucleotide-binding sites in the γ subunit lie very close together, and the side 336 
chains of some conserved basic residues (e.g. H150 and H297 in rat γ1) make interactions with the 337 
phosphate groups of more than one nucleotide (31). It is therefore not surprising that mutations 338 
affecting binding of a nucleotide at one site can also affect binding and function at other sites. For 339 
example, mutation to alanine of any one of the three aspartate residues that define sites 1, 3 and 4 340 
(D89 in CBS1, D244 in CBS3 and D316 in CBS4, rat γ1) affects not only allosteric activation but 341 
also T172 phosphorylation (24). That the model of Xiao et al (32) is an oversimplification is also 342 
suggested by a recent study in which a core AMPK complex was crystallized in the presence of 343 
ATP rather than AMP. In this structure, ATP was found in sites 1 and 4, with site 3 being empty; it 344 
was also suggested that the mode of ATP binding in site 4 would preclude binding of any 345 
nucleotide at site 3 (9). Xiao et al had previously proposed that site 4 was a “non-exchangeable” site 346 
at which AMP bound tightly and irreversibly (31). It is clear that the roles of the three γ subunit 347 
nucleotide-binding sites on AMPK function are complex, and remain incompletely understood. 348 
Of the three effects of the K475E mutation on AMPK function, which is the most likely to 349 
cause the clinical problems for the patient? The K475E mutation causes both loss-of-function and 350 
gain-of-function effects. The loss-of-function effects are the reduced allosteric activation by AMP, 351 
and the reduced ability of cellular stresses such as phenformin to increase T172 phosphorylation as 352 
seen in both HEK293 and H9c2 cells. We suspect that these effects could be compensated for by 353 
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the γ1 isoform, which is expressed along with γ2 in developing and adult mouse heart, and adult 354 
human heart (19,26), and appears to account for about 80% of total AMPK activity in adult rat heart 355 
(13). Both the de novo and inherited mutations in the PRKAG2 gene are dominant in effect, and 356 
increased basal activity and T172 phosphorylation have been previously reported for the R531G, 357 
R531Q and R384T mutations, with both of the latter being de novo mutations that caused severe 358 
disease leading to death in early life (1,8). Our study in H9c2 cells showed a significant reduction in 359 
T172 phosphorylation and reduced response to phenformin. Thus, cell environment appears to be 360 
important in studying this gene mutation. The K475E mutation induced inhibition of AMPK 361 
observed in H9c2 cells is in agreement with the structural modeling results where the mutation 362 
causes disruption of electrostatic interactions with adenine nucleotides. Activation of AMPK is well 363 
known to inhibit downstream signaling pathway, including the mTOR which plays a critical roles in 364 
regulation of cell growth. Since we observed a markedly increases in phosphorylation of p70S6K, 365 
S6 and 4E-BP1 in K475E expressing H9c2 cells and the patient with the mutation, a loss-of-366 
function K475E phenotype seems logical.  367 
mTOR functions by interacting with several adaptor proteins to form two distinct multiprotein 368 
complexes: mTOR complex 1 (mTORC1) and mTORC2. mTORC1 is a critical regulator of protein 369 
synthesis, cell growth and proliferation and many other metabolic processes (28). p70S6K is 370 
required for G1 cell cycle progression and cell growth. Phosphorylation of p70S6K is required for 371 
its activation and T389 is the principal regulatory phosphorylation site. 4E-BP1 is a translation 372 
repressor protein. It functions by binding to the eukaryotic translation initiation factor 4E (eIF4E). 373 
Only when being hyperphosphorylated would 4E-BP1 stop interaction with eIF4E which results in 374 
activation of cap-dependent translation (25). Since both p70S6K and 4E-BP1 are considered 375 
downstream of mTORC1 and can be phosphorylated by mTOR, we examined phosphorylation of 376 
these two critical signaling factors to determine changes in cell growth response by the K475E 377 
mutation. We observed significant increases in p70S6K phosphorylation at T389 as well as Ser-378 
421/T424 sites with the K475E mutation. Not surprisingly ribosomal protein S6 phosphorylation 379 
(S235/S236 and S240/S244) was also significantly increased. A noted hyper-phosphorylation was 380 
also found with the K475E mutation. These changes were consistent in H9c2 cells as well as in the 381 
patient fibroblasts. These observations suggest that the K475E mutation induces activation of cell 382 
growth pathway downstream of mTOR. Our next step, logically, is to test the therapeutic potential 383 
17 
 
of mTOR inhibition in ameliorating PRKAG2 mutation-induced changes in vivo. Using H9c2 cells 384 
we demonstrated that cell hypertrophy induced by the K475E mutation can be reversed by 385 
rapamycin. This is encouraging as to date there is no targeted therapy for PRKAG2 HCM. Hence, 386 
the next step would be to develop transgenic mouse models to demonstrate the effectiveness of the 387 
mTOR inhibition strategy in treating PRKAG2 mutation-induced HCM.  388 
Overall, our data show that a novel, de novo K475E PRKAG2 mutation causing hypertrophic 389 
cardiomyopathy. The K475E mutation induces changes in the AMPK complex that are not shared 390 
by the other PRKAG2 mutations. The K475E mutation also induces activation of cell growth 391 
pathways and hypertrophy which can be effectively reversed by rapamycin treatment. 392 
 393 
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Figure Legends: 518 
 519 
Figure 1.  Amino acid alignment of γ2-subunit of AMPK and echocardiogram of the patient 520 
with the K475E mutation. (A) Family pedigree of the PRKAG2 K475E carrier.  (B) Lysine at 475 521 
position in the CBS3 repeat of the γ2 isoform of AMPK is conserved among all species. A K485E 522 
mutation at the linker region between CBS3 and CBS4 was recently reported (21). (C) The 523 
echocardiogram was taken at 7 month old when the patient was being treated for hypertrophy 524 
cardiomyopathy. 525 
 526 
Figure 2.  Effects of the K475E mutation on activity of AMPK in HEK-293 cells. (A) Effect of 527 
AMP on absolute AMPK activity. HEK-293 cells stably expressing FLAG-tagged wild type (WT) 528 
γ2 or a K475E mutant were lysed, AMPK immunoprecipitated using anti-FLAG antibodies and 529 
kinase activity assayed at different AMP concentrations. Data (mean ± SEM, triplicate assays) were 530 
fitted to the equation: Y=basal+(((activation*basal-basal)*X)/(EC50+X))-531 
(((activation*basal)*X)/(IC50+X)), where Y is activity, X is AMP concentration, EC50 is the 532 
concentration of AMP giving half-maximal activation and IC50 is the concentration of AMP giving 533 
half-maximal inhibition (AMP inhibits at high concentration due to competition with ATP at the 534 
catalytic site). The curves were generated by the following best-fit parameters: WT: basal = 0.027 ± 535 
0.002 nmol/min/mg, activation = 3.9 ± 0.4-fold, EC50 = 6.2 ± 2.0 µM, IC50 = 1.5 ± 0.5 mM; K475E: 536 
basal = 0.21 ± 0.01 nmol/min/mg, activation ≈ 2-fold, EC50 ≈ 100 µM, IC50 ≈ 1 mM. (B) Effect of 537 
AMP on relative AMPK activity. As (A), but expressing kinase activity relative to the activity in 538 
the absence of AMP. 539 
 540 
Figure 3.  Effects of the K475E mutation on response to phenformin treatment in HEK-293 541 
cells. Cells stably expressing FLAG-tagged wild type (WT) γ2, R531G or K475E mutants were 542 
treated with or without phenformin (1.25 mM) for 1 hr, AMPK immunoprecipitated using anti-543 
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FLAG antibody and assayed at 200 µM AMP (upper panel). The lower panel shows the signal 544 
obtained using anti-pT172 antibody by Western blotting of immunoprecipitates and expressed 545 
relative to the signal obtained using anti-FLAG antibody. Data are mean ± SEM (n = 3) and 546 
statistical significance determined by 1-way ANOVA (*P <0.05, **P <0.01, ***P <0.001). ns, not 547 
significant. 548 
 549 
Figure 4.  Structural analysis of the role of the equivalent K242 residue in rat γ1, and 550 
sequence conservation around K475 in AMPK isoforms. Models of rat γ1 showing the 551 
relationship of D89, H150, R223 and K242 with bound AMP (A), ADP (B) and ATP (C) using 552 
RCSB Protein Data Bank ID 2V8Q, 2Y8L and 2V9J, respectively (24, 30; www.rcsb.org). Models 553 
were constructed using MacPyMol molecular visualization system with CBS1 (cyan), CBS2 554 
(magenta), CBS3 (blue) and CBS4 (orange) in “cartoon” representation and nucleotides and 555 
highlighted residues in stick representation (C atoms in grey in side chains and green in nucleotides; 556 
O atoms blue, N atoms red, P atoms orange). (D) Alignment of sequences around K475 in human 557 
γ2 and equivalent residues in other species and isoforms. 558 
 559 
Figure 5.  Overexpression of the K475E mutant in H9c2 cells results in AMPK inhibition and 560 
hypertrophy. H9c2 cells were stably transfected with the human PRKAG2 wild type (WT) or the 561 
K475E mutant construct. (A) Cells were treated with vehicle or phenformin (1.25 mM) for 1, 4 or 562 
24 hours.  Shown are representative Western blots with antibody against phospho- AMPKα (T172) 563 
or AMPKα. (B) Densitometric scanning results of Western blots were shown in (A). Each bar 564 
represents measurement of phospho- AMPKα normalized with AMPKα from 3-4 separate 565 
experiments. * P < 0.05 vs. vehicle control within each gene expression group. # P < 0.05 vs. 566 
vehicle control of WT group. (C) Cells were trypsinized and analyzed by flow cytometry. Forward 567 
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scatter (FSC) was used to determine relative cell volume. Ten thousand cells each were analyzed 568 
for WT- (white histogram) and the K475E mutant-expressing (shaded histogram) cells. 569 
 570 
Figure 6.  Overexpression of the K475E mutant in H9c2 cells induces activation of cell growth 571 
signaling pathways. H9c2 cells were stably transfected with the human PRKAG2 wild type (WT) 572 
or the K475E mutant construct. Shown are representative Western blots performed on cell lysates 573 
with an antibody against phospho- p70S6K (T389), phospho- p70S6K (T421/S424), phospho- S6 574 
(S235/S236), phospho- S6 (S240/S244), phospho- 4E-BP1 (T37/T46), phospho- 4E-BP1 (S65), 575 
phospho- 4E-BP1 (T70), phospho- AKT (S473), or phospho- AKT (T308). Blots of each individual 576 
total protein (p70S6K, S6, 4E-BP1, AKT) were also included. Densitometric scanning results of 577 
Western blots of H9c2 cells overexpressing human wild type (WT) or the K475E mutant 578 
PRKAG2. Each bar represents measurement of each phospho-specific antibody normalized with its 579 
individual total antibody from 3-4 separate experiments. * P < 0.05 vs. individual WT. 580 
 581 
Figure 7.  Primary fibroblasts from the patient with the K475E mutation show activated cell 582 
growth signaling pathways. Fibroblasts from the patient with the K475E mutation and multiple 583 
controls were cultured. Western blots were performed on cell lysates with an antibody against 584 
phospho- p70S6K (T389), phospho- p70S6K (T421/S424), phospho- S6 (S235/S236), phospho- S6 585 
(S240/S244), phospho- 4E-BP1 (T37/T46), phospho- 4E-BP1 (S65), phospho- 4E-BP1 (T70), 586 
phospho- AKT (S473), or phospho- AKT (T308). Blots of each individual total protein (p70S6K, 587 
S6, 4E-BP1, AKT) were also included. Densitometric scanning results of Western blots of 588 
primary fibroblasts from the patient with the K475E mutation and multiple age- or/and sex-589 
matched controls. Each bar represents measurement of each phospho-specific antibody normalized 590 
with its individual total antibody from 3-4 separate experiments. * P < 0.05 vs. individual WT. 591 
 592 
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Figure 8.  Angiotensin II (Ang II) induces H9c2 cell hypertrophy which can be reversed by 593 
rapamycin treatment. (A) H9c2 cells overexpressing the human PRKAG2 wild type (WT) or the 594 
K475E mutant were treated with vehicle (Control), 200 nM Ang II, 50 nM rapamycin or Ang II in 595 
combination with rapamycin for 24 hours before stained for green fluorescent Calcein AM for 596 
microscopic assessment of cell area. (B) The bar graphs show the quantification results (n = 60-80 597 
cells) from four individual experiments. * P < 0.05 vs. WT within the same treatment group. + P < 598 
0.05 vs. vehicle control. 599 
 600 
Figure 9.  Hypertrophy phenotype induced by overexpression of the K475E mutant in H9c2 601 
cells can be corrected by rapamycin treatment. (A) H9c2 cells overexpressing the human 602 
PRKAG2 wild type (WT) or the K475E mutant were treated with vehicle (Control) or 50 nM 603 
rapamycin for the indicated period of time. Cell area was assessed as described in Figure 8. Each 604 
bar represents measurement of cell area from three to four separate experiments (n = 60-80 cells). * 605 
P < 0.05 vs. individual control of the same genotype and treatment day group. (B) The time- course 606 
effect of rapamycin treatment presented as cell area reduction (%) based on the data in (A). 607 
 608 
  609 
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Table 1. Known human PRKAG2 mutations and their cardiac phenotypes 610 
 N- CBS1 L1 CBS2 L2 
  
G1
00
S  
R3
02
Q 
M
33
5T
 
H3
44
P 
H3
83
R 
R3
84
T 
T4
00
N  
Early 
onset 
        X X      
AMPK 
activity 
↓     ↑   
Myofibrillar 
disarray 
        
Reference 34, 35 2, 10 
 
 27 6 1 2 
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 CBS3 L3 CBS4 C- 
 
 K4
75
E 
K4
85
E 
Y4
87
H 
N4
88
I 
E5
06
K 
E5
06
K 
* 
H5
30
R 
R5
31
G 
#  
R5
31
Q 
S5
48
P 
 
Early 
onset 
X          X X X X   
AMPK 
activity 
↓       ↑ ↑   
Myofibrillar 
disarray 
 
? 
 
X 
 
 
     
 
 
X 
  
Reference  
 
21 3 2, 22 5 16 23 11 8 20  
L, linker region. 612 
* No significant glycogen accumulation 613 
# No hypertrophy 614 
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